Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis.

08:00 EDT 18th March 2020 | BioPortfolio

Summary of "Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis."

Sands et al. expand the therapeutic potential of anti-IL-12/IL-23 blockade in IBD, by demonstrating a clear clinical benefit of ustekinumab as induction and maintenance therapy for ulcerative colitis (UC). The UNIFI trial had a double-blind, placebo-control design and consisted of an 8-week induction and a 44-week randomized-withdrawal maintenance trial. Patients with active, moderate-to-severe UC (total Mayo score of 6-12 with endoscopic subscore of ≥2 via central reading) were recruited from 244 centers worldwide. Patient characteristics were similar across groups in the induction and maintenance arms. Half of the patients who were randomized for the induction trial reported a history of treatment failure with biologics, among whom, 98.8% had failed at least one TNF antagonist, 32.6% both a TNF antagonist and vedolizumab, and 1.2% vedolizumab only.


Journal Details

This article was published in the following journal.

Name: Gastroenterology
ISSN: 1528-0012


DeepDyve research library

PubMed Articles [17621 Associated PubMed Articles listed on BioPortfolio]

Blockade of CCR5 in melanoma: an alternative immune checkpoint modulator.

Melanoma is a deadly tumor which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors. Ho...

p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.

Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of cancer, including prostate cancer...

Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma.

: Glioblastoma (GBM) is a highly aggressive brain tumor and is one of the most lethal human cancers. Chimeric antigen receptor (CAR) T cell therapy has markedly improved survival in previously incurab...

Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?

The efficacy of faecal microbiota transplantation (FMT) in Crohn's disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD-related clinical targets...

Desmoplastic small round cell tumour (DSRCT): emerging therapeutic targets and future directions for potential therapies.

Clinical Trials [5519 Associated Clinical Trials listed on BioPortfolio]

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)

The purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of NHS-IL12 when given in combination with a fixed avelumab dose in subjects with metas...

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with c...

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Background: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people livin...

Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of ...

Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma

This is a phase 2, single-arm, multicenter clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade combined with induction chemotherapy and radiot...

Medical and Biotech [MESH] Definitions

The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

An analytical method for detecting and measuring FLUORESCENCE in compounds or targets such as cells, proteins, or nucleotides, or targets previously labeled with FLUORESCENCE AGENTS.

Cognitive mechanism based on expectations or beliefs about one's ability to perform actions necessary to produce a given effect. It is also a theoretical component of behavior change in various therapeutic treatments. (APA, Thesaurus of Psychological Index Terms, 1994)

The non-genetic biological changes of an organism in response to challenges in its ENVIRONMENT.

Quick Search

DeepDyve research library

Searches Linking to this Article